Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting
GALECTIN (NASDAQ: GALT) Delayed: 2.67 +0.06 (2.30%)
Previous Close $2.61    52 Week High $3.05 
Open $2.61    52 Week Low $0.49 
Day High $2.76    P/E N/A 
Day Low $2.58    EPS $-1.32 
Volume 282,138